Archives
The non-approval of aducanumab in Europe still marks a significant stride forward in dementia research
17 December 2021
![](https://news.joindementiaresearch.nihr.ac.uk/wp-content/uploads/2021/12/JOB-head-and-shoulders_2019-150x150.png)
An opinion piece by Professor John O’Brien, NIHR Clinical Research Network National Specialty Lead for Dementias The European Medicines Agency (EMA) has today said no to approving aducanumab – a new drug to treat Alzheimer’s disease. EMA considered that although the drug removed amyloid, a toxic protein that builds up in the brains of people […]